Personalis (NASDAQ:PSNL) Research Coverage Started at Craig Hallum

Craig Hallum started coverage on shares of Personalis (NASDAQ:PSNL) in a research note released on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $8.00 target price on the stock.

Several other analysts have also issued reports on the stock. Needham & Company LLC reduced their price objective on shares of Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Lake Street Capital boosted their price objective on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Personalis in a report on Friday, February 28th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $7.80.

Personalis Trading Up 2.2 %

Shares of PSNL stock opened at $3.67 on Monday. The company’s 50-day moving average price is $4.83 and its 200-day moving average price is $4.88. The stock has a market cap of $323.93 million, a price-to-earnings ratio of -2.18 and a beta of 1.73. Personalis has a twelve month low of $1.14 and a twelve month high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. The firm had revenue of $16.80 million for the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. As a group, equities research analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Personalis during the fourth quarter worth approximately $28,000. JPMorgan Chase & Co. increased its stake in shares of Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after buying an additional 5,654 shares during the period. Olympiad Research LP purchased a new stake in shares of Personalis during the fourth quarter worth approximately $59,000. Alpine Global Management LLC purchased a new stake in shares of Personalis during the fourth quarter worth approximately $60,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Personalis during the fourth quarter worth approximately $63,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.